Table 2.
Number of patients on SU in CVOTs control and treatment groups.
| Name of the CVOT | Number of patients on SU in control group (% of patients) | Number of patients on SU in treatment group |
|---|---|---|
| LEADER [28] | 2363 (50.6) | 2370 (50.8) |
| ELIXA [29] | 1016 (33.5) | 988 (32.6) |
| HARMONY [30] | 1379 (29) | 1346 (28) |
| ORIGIN [31] | 1810 (28.9) | 1901 (30.3) |
| DECLARE-TIMI 58[25] | 3707 (43.2) | 3615 (42.1) |
| EMPA-REG [24] | 220 (39.1) | 440 (37.4) |
| TECOS [26] | 3299 (45.0) | 3346 (45.6) |
| EXAMINE [27] | 1237 (46.2) | 1266 (46.9) |
| CARMELINA33,34 | 1140 (32.7) | 1102 (31.5) |
LEADER: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Trials; ELIXA: Evaluation of Lixisenatide in Acute Coronary Syndrome; HARMONY: Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus; ORIGIN: Outcome Reduction with Initial Glargine Intervention; DECLARE-TIMI 58: Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Event; ESRD: End-stage renal disease; EMPA-REG: Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus; TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin; EXAMINE: Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care; CARMELINA: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus.